Sorafenib Inhibits LPS-induced Inflammation by Regulating Lyn-MAPK-NF-kB/AP-1 Pathway and TLR4 Expression
Overview
Authors
Affiliations
Sorafenib is an anti-tumor drug widely used in clinical treatment, which can inhibit tyrosine kinase receptor on cell surface and serine/threonine kinase in downstream Ras/MAPK cascade signaling pathway of cells. Tyrosine kinase phosphorylation plays an important role in inflammatory mechanism, such as TLR4 tyrosine phosphorylation, MAPK pathway protein activation, and activation of downstream NF-кB. However, the effects of sorafenib on LPS-induced inflammatory reaction and its specific mechanism have still remained unknown. We found that sorafenib inhibited the phosphorylation of tyrosine kinase Lyn induced by LPS, thereby reducing the phosphorylation level of p38 and JNK, inhibiting the activation of c-Jun and NF-κB, and then inhibiting the expression of inflammatory factors IL-6, IL-1β, and TNF-α. Furthermore, sorafenib also decreased the expression of TLR4 on the macrophage membrane to inhibit the expression of inflammatory factors latterly, which may be related to the inactivation of Lyn. These results provide a new perspective and direction for the clinical treatment of sepsis.
Cao D, Woo M, Kim E, Ahn B, Prayoga A, Kang S Food Sci Nutr. 2024; 12(11):9566-9576.
PMID: 39619973 PMC: 11606880. DOI: 10.1002/fsn3.4518.
Li D, Li F, Zhou Y, Tang Y, Hu Z, Wu Q Foods. 2024; 13(18).
PMID: 39335912 PMC: 11431537. DOI: 10.3390/foods13182984.
Anti-Inflammatory Effects of Paraprobiotic KU15122 in LPS-Induced RAW 264.7 Cells.
Lee H, Jung H, Lee N, Paik H J Microbiol Biotechnol. 2024; 34(7):1491-1500.
PMID: 38960876 PMC: 11294648. DOI: 10.4014/jmb.2404.04052.
Zhou Y, Li Z, Yu S, Wang X, Xie T, Zhang W Ren Fail. 2024; 46(1):2327498.
PMID: 38666363 PMC: 11057400. DOI: 10.1080/0886022X.2024.2327498.
Park M, Park M, Jang H, Lee S, Hwang Y, Park S PLoS One. 2024; 19(3):e0299792.
PMID: 38536854 PMC: 10971663. DOI: 10.1371/journal.pone.0299792.